BALKAN MEDICAL JOURNAL, cilt.32, sa.3, ss.266-272, 2015 (SCI-Expanded)
Background: The use of pegylated interferon alpha and ribavirin (PegIFN/RBV) for the retreatment of chronic hepatitis C virus (HCV) infection without a sustained virological response (SVR) prior to PegIFN/RBV treatment has resulted in low success rates.